| Nicholas Dyson | |
| Workplaces: | Massachusetts General Hospital Cancer Center |
| Academic Advisors: | Ed Harlow |
| Doctoral Students: | Simon Boulton Adam Brook |
| Known For: | E2F and pRB |
Nicholas Dyson is Professor of Medicine at Harvard Medical School, the James and Shirley Curvey MGH Research Scholar and Scientific Director of the Massachusetts General Hospital Cancer Center.[1]
The Dyson Lab studies the retinoblastoma protein.
Working as a post-doctoral fellow in the laboratory of Dr. Ed Harlow, Dyson demonstrated that the retinoblastoma protein can form complexes in vitro with the E7 oncoprotein of Human papilloma virus type-16.[2] This result implicated pRB binding to E7 as a step in human papilloma virus-associated carcinogenesis.
More recently, Dyson's group has shown that the transcription factor E2F1 is a potent and specific inhibitor of beta-catenin/T-cell factor (TCF)-dependent transcription, and that this function contributes to E2F1-induced apoptosis.[3]
As of 2015, Professor Dyson has 140 publications in leading peer-reviewed journals.